Q1 2025 Catalyst Pharmaceuticals Inc Earnings Call Transcript

May 8, 2025 / 12:30 PM GMT

Release Date Price: €20.33 (-1.50%)

Transcript 10-Q

Key Points

Positve

Catalyst Pharmaceuticals Inc (CPRX) reported a 43.6% year-over-year increase in total net revenues, reaching $141.4 million.
The company maintains a strong cash position of $580.7 million, supporting long-term growth and strategic priorities.
Firdapse showed a 25.3% year-over-year revenue increase, driven by strong adoption among newly diagnosed patients.
Agamree's net product revenues increased significantly to $22 million, reflecting its first full year of commercial availability.
Catalyst Pharmaceuticals Inc (CPRX) reaffirmed its full-year total product revenue guidance of between $545 million to $565 million, indicating confidence in sustained growth.

Negative

The company faces potential revenue decline for Fycompa due to the anticipated generic entry after May 23, 2025.
There is ongoing litigation with two remaining first filers regarding generic entry, creating uncertainty around intellectual property protection.
The cybersecurity incident in Q1 2024 affected prescription activity, although it has since normalized.
The company anticipates increased cost of sales due to higher royalty obligations as product sales exceed certain thresholds.
Despite strong performance, the company remains conservative in its revenue guidance for Firdapse, potentially underestimating growth opportunities.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CPRX.OQ - Catalyst Pharmaceuticals Inc
Q1 2025 Catalyst Pharmaceuticals Inc Earnings Call
May 08, 2025 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day everyone and welcome to today's Catalyst Pharmaceuticals 1st quarter 2025 financial results conference call.

At this time, all participants are in a listen-only mode.

Later you will have an opportunity to ask questions during the question and answer session.

You may register to ask a question at any time by pressing the star and one keys on your telephone keypad.

Please note this call is being recorded and that I will be standing by should you need any assistance.

It is now my pleasure to turn today's program over to Mike Kalb, CFO. Please begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.